After backlash, Teva to resume supplies of critical children's cancer drug

After backlash, Teva to resume supplies of critical children's cancer drug

STAT Plus: After backlash, Teva will resume supplies of a critical children’s cancer medicine

By ED SILVERMAN

ED UTHMAN/CREATIVE COMMONS

At the time Teva halted production last July, there was no available alternative for vincristine, which is used to treat several childhood cancers.

READ MORE